On January 27, 2026, Integrated Biosciences, a Redwood City-based biotechnology firm, announced the appointment of Daniel J. Anderson, PhD, as its new Chief Scientific Officer (CSO). Dr. Anderson brings a wealth of expertise from his previous roles at Eikon Therapeutics, Recursion Pharmaceuticals, Cleave Biosciences, and Genentech.
Integrated Biosciences specializes in merging synthetic biology, chemistry, and artificial intelligence to discover small-molecule therapeutics targeting age-related diseases. The company’s proprietary platform utilizes a tight coupling of precise biological perturbations with high-content measurements and AI-driven analysis.
Roles and Strategic Objectives for the New CSO:
-
Scientific Oversight: Dr. Anderson will lead the company’s scientific strategy and oversee the expansion of its drug discovery pipeline.
-
Proven Track Record: Having successfully transitioned 10 programs into clinical stages throughout his 20-year career, his leadership is expected to accelerate the translation of laboratory discoveries into clinical treatments for patients.
-
Executive Leadership Transition: In conjunction with this appointment, co-founder Max Wilson, PhD, will transition to the role of Chief Technology Officer (CTO), where he will focus on scaling the core platform and advancing next-generation AI-enabled discovery tools.
The addition of Dr. Anderson underscores the strength of Integrated Biosciences’ research capabilities and signals a new phase of growth in the development of innovative medicines for aging populations.
Source: https://www.contractpharma.com/breaking-news/integrated-biosciences-names-daniel-j-anderson-cso/